Wall Street Slips to a Rare Back-To-Back Loss
U.S. stock indexes drifted lower in the runup to the highlight of the week for the market, the latest update on inflation
All Posts in "News Team"
Parexel powers up real-world research capabilities with new senior vice president
Parexel, a global contract research organization headquartered in Durham, North Carolina, is beefing up its ability to gather real-world data by bringing Mike D’Ambrosio on board as senior vice president and global head of real world research.
Abbott kicks off deep-brain stimulation trial in treatment-resistant depression
Abbott has launched a pivotal clinical trial to see if its deep-brain stimulation approach can make headway against treatment-resistant depression.
Moderna’s mpox vaccine prevents severe symptoms in monkeys compared to Bavarian Nordic’s Jynneos
A new type of mpox, clade Ib, has been spreading rapidly within the Democratic Republic of Congo and leaking outside the African nation’s borders since Sept. 2023. In response, the World Health Organization (WHO) declared the outbreak a public health emergency of international concern (PHEIC) last month, the second such declaration for an mpox variant in the past two years.
Athira’s phase 2/3 Alzheimer’s trial falls short, sinking stock
Athira Pharma’s tumultuous journey to phase 2/3 Alzheimer’s disease data has ended in failure. The trial found fosgonimeton was no better than placebo on the primary and key secondary endpoints, driving investors to cut the cord holding up the biotech’s stock price.
BioAge files for IPO, plans pair of midstage obesity trials
After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market.
ArsenalBio raises $325M for solid tumor CAR-T science with Regeneron and BMS in tow
Arsenal Biosciences is moving on up. The cell therapy company has added on $325 million in ammunition with big-name backers like Regeneron joining the artillery as the biotech sets out to build the biggest—and best—house on the block.
Eli Lilly bets $1B in biobucks on Haya to scour dark genome for obesity targets
Eli Lilly’s hunt for obesity targets has led it to the dark genome. The Big Pharma has put together a deal worth up to $1 billion in biobucks to partner with Haya Therapeutics to find multiple regulatory-genome-derived RNA-based drug targets.
Aelis’ cannabis use drug flunks phase 2b, driving Indivior to rethink $100M option
Aelis Farma’s hopes of securing a quick, positive decision on a $100 million option payment have gone up in smoke. The French biotech reported the failure of its phase 2b cannabis use disorder (CUD) study Wednesday, prompting its partner Indivior to say it doesn’t currently expect to exercise its option.
Planet Labs Shares Drop After 4Q Outlook, 3Q Results Miss Estimates
Shares of Planet Labs on Monday dropped after the company provided a guidance for the fourth quarter that missed analysts expectations following weaker-than-expected third-quarter results.
Drug based on anti-nausea agent reduces Alzheimer’s-advancing astrocytes in mice, biotech says
FDA elevates recall as Zimmer Biomet phases out hip replacement implant
Alkeus’ oral eye disease asset fails to significantly reduce lesion growth in phase 3
Rakovina deepens AI focus with cancer collab to select DNA-damage response kinase targets
FDA clears Senseonics’ 365-day Eversense CGM implant
Merck, Daiichi rack up phase 3 ADC lung cancer win but report 2 deaths, immature OS data
Ascendis’ dwarfism drug accelerates growth in phase 3, teeing up challenge to BioMarin
Trispecific antibody from Ichnos Glenmark Innovation beats J&J’s Tecvayli at treating multiple myeloma in mice
American Consumers Feeling Less Confident in December, Conference Board Says
Biden Will Decide on US Steel Acquisition After Influential Panel Fails to Reach Consensus